Oncology and Hematology - Global Oncology Academy

417-432 of 651

Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
MinuteCE®
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
MinuteCE®
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
MinuteCE®
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
MinuteCE®
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 credit 10 episodes
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 credit 10 episodes
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
MinuteCE®
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
MinuteCE®
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
MinuteCE®
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Navigating mCRPC Treatment: A Look at Abiraterone and Enzalutamide
Navigating mCRPC Treatment: A Look at Abiraterone and Enzalutamide
Project Oncology®
Navigating mCRPC Treatment: A Look at Abiraterone and Enzalutamide
Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
Project Oncology®
Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
Charles Turck, PharmD, BCPS, BCCCP; Hannah McManus, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Hannah McManus, MD
- Andrew Armstrong, MD, MSc
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CE
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Joyce O'Shaughnessy, MD
0.25 credits
- Joyce O'Shaughnessy, MD
0.25 credits
How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
Project Oncology®
How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
Daniel Kwon, MD
- Daniel Kwon, MD
Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
Project Oncology®
Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
Treatment Selection Strategies for Metastatic Breast Cancer Patients
Treatment Selection Strategies for Metastatic Breast Cancer Patients
Project Oncology®
Treatment Selection Strategies for Metastatic Breast Cancer Patients
Sarah Sammons, MD
- Sarah Sammons, MD
Emerging Metastatic Breast Cancer Therapies: From CDK Inhibitors to SERDs and Beyond
Emerging Metastatic Breast Cancer Therapies: From CDK Inhibitors to SERDs and Beyond
Project Oncology®
Emerging Metastatic Breast Cancer Therapies: From CDK Inhibitors to SERDs and Beyond
Sarah Sammons, MD
- Sarah Sammons, MD
Detecting Metastatic Breast Cancer: The Role of Scans and Emerging Blood Tests
Detecting Metastatic Breast Cancer: The Role of Scans and Emerging Blood Tests
Project Oncology®
Detecting Metastatic Breast Cancer: The Role of Scans and Emerging Blood Tests
Sarah Sammons, MD
- Sarah Sammons, MD

27/11